Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

179 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Crohn's Disease Mortality and Ambient Air Pollution in New York City.
Feathers A, Lovasi GS, Grigoryan Z, Beem K, Datta SK, Faleck DM, Socci T, Maggi R, Swaminath A. Feathers A, et al. Among authors: swaminath a. Inflamm Bowel Dis. 2023 Nov 2:izad243. doi: 10.1093/ibd/izad243. Online ahead of print. Inflamm Bowel Dis. 2023. PMID: 37934758
Predictors and Management of Loss of Response to Vedolizumab in Inflammatory Bowel Disease.
Shmidt E, Kochhar G, Hartke J, Chilukuri P, Meserve J, Chaudrey K, Koliani-Pace JL, Hirten R, Faleck D, Barocas M, Luo M, Lasch K, Boland BS, Singh S, Vande Casteele N, Sagi SV, Fischer M, Chang S, Bohm M, Lukin D, Sultan K, Swaminath A, Hudesman D, Gupta N, Kane S, Loftus EV Jr, Sandborn WJ, Siegel CA, Sands BE, Colombel JF, Shen B, Dulai PS. Shmidt E, et al. Among authors: swaminath a. Inflamm Bowel Dis. 2018 Oct 12;24(11):2461-2467. doi: 10.1093/ibd/izy171. Inflamm Bowel Dis. 2018. PMID: 29788240 Free PMC article.
Retrospective Analysis of Safety of Vedolizumab in Patients With Inflammatory Bowel Diseases.
Meserve J, Aniwan S, Koliani-Pace JL, Shashi P, Weiss A, Faleck D, Winters A, Chablaney S, Kochhar G, Boland BS, Singh S, Hirten R, Shmidt E, Hartke JG, Chilukuri P, Bohm M, Sagi SV, Fischer M, Lukin D, Hudesman D, Chang S, Gao Y, Sultan K, Swaminath A, Gupta N, Kane S, Loftus EV Jr, Shen B, Sands BE, Colombel JF, Siegel CA, Sandborn WJ, Dulai PS. Meserve J, et al. Among authors: swaminath a. Clin Gastroenterol Hepatol. 2019 Jul;17(8):1533-1540.e2. doi: 10.1016/j.cgh.2018.09.035. Epub 2018 Sep 27. Clin Gastroenterol Hepatol. 2019. PMID: 30268561 Free PMC article.
Escalation of Immunosuppressive Therapy for Inflammatory Bowel Disease Is Not Associated With Adverse Outcomes After Infection With Clostridium difficile.
Lukin DJ, Lawlor G, Hudesman DP, Durbin L, Axelrad JE, Passi M, Cavaliere K, Coburn E, Loftus M, Jen H, Feathers A, Rosen MH, Malter LB, Swaminath A; IBD-ReMEdY Study (Research, Mentoring, Education New York). Lukin DJ, et al. Among authors: swaminath a. Inflamm Bowel Dis. 2019 Mar 14;25(4):775-781. doi: 10.1093/ibd/izy308. Inflamm Bowel Dis. 2019. PMID: 30312400
Shorter Disease Duration Is Associated With Higher Rates of Response to Vedolizumab in Patients With Crohn's Disease But Not Ulcerative Colitis.
Faleck DM, Winters A, Chablaney S, Shashi P, Meserve J, Weiss A, Aniwan S, Koliani-Pace JL, Kochhar G, Boland BS, Singh S, Hirten R, Shmidt E, Kesar V, Lasch K, Luo M, Bohm M, Varma S, Fischer M, Hudesman D, Chang S, Lukin D, Sultan K, Swaminath A, Gupta N, Siegel CA, Shen B, Sandborn WJ, Kane S, Loftus EV Jr, Sands BE, Colombel JF, Dulai PS, Ungaro R. Faleck DM, et al. Among authors: swaminath a. Clin Gastroenterol Hepatol. 2019 Nov;17(12):2497-2505.e1. doi: 10.1016/j.cgh.2018.12.040. Epub 2019 Jan 6. Clin Gastroenterol Hepatol. 2019. PMID: 30625408 Free PMC article.
179 results